Strategic partnerships LabGenius has active collaboration momentum with Sanofi and LG Chem, indicating a strong appetite from large pharma for AI-driven antibody discovery. This suggests opportunities to approach mid-to-large biopharma players for co-development, licensing, or platform integration deals aligned with EVA and selectivity-enhanced antibodies.

AI driven platform The EVA platform combines AI, robotics, and synthetic biology to accelerate antibody discovery with best-in-class killing profiles. This differentiates LabGenius in a crowded market and presents sales angles around accelerated timelines, reduced R&D risk, and access to cutting-edge computational/automation capabilities for potential partners.

Clinical and preclinical momentum Upcoming preclinical data for LGTX-101 and participation in AACR 2026 demonstrate active pipeline progression and visibility in the oncology field. Use this to position expansion discussions around new targets, co-development of selectivity-enhanced antibodies, and potential milestone-driven collaborations.

Funding and growth With funding of 73 million and ongoing investor support, LabGenius has capital to scale partnerships and expand capabilities. This can be leveraged to negotiate milestone-based deals, joint ventures, or regional partnerships with favorable terms for rapid collaboration and scale-up.

Market differentiation Focus on LabGenius’ selectivity-enhanced antibodies for solid tumors and AI-designed tumor-targeting antibodies as a competitive edge. This creates opportunities to target oncology portfolios seeking next-generation mechanisms, antibody-drug conjugates, or bispecific formats with a clear value proposition and potential for licensing access to EVA-derived assets.